McMaster

Fuzionaire Diagnostics Enters Agreement with McMaster University to Expand Capabilities in Developing Theranostic Radiopharmaceuticals

Retrieved on: 
Wednesday, June 29, 2022
Other Health, Research, Pharmaceutical, Oncology, Training, Other Education, University, Education, Science, Biotechnology, Other Science, Health, Associate professor, University, Personalized medicine, Ligand, Student, Cancer, McMaster, Chemistry, McMaster University, PET, Neoplasm, Doctor of Philosophy, Radiochemistry, Principal investigator, Diagnosis, Medical imaging, Nobel, California Institute of Technology

Fuzionaire Diagnostics, Inc. ("Fuzionaire Dx") today announced a collaborative research agreement with McMaster University ("McMaster") under which theranostic radiopharmaceuticals developed with Fuzionaire Dx's HetSiFA platform will be evaluated at McMaster's comprehensive preclinical nuclear medicine facilities.

Key Points: 
  • Fuzionaire Diagnostics, Inc. ("Fuzionaire Dx") today announced a collaborative research agreement with McMaster University ("McMaster") under which theranostic radiopharmaceuticals developed with Fuzionaire Dx's HetSiFA platform will be evaluated at McMaster's comprehensive preclinical nuclear medicine facilities.
  • The collaboration expands Fuzionaire Dxs capabilities to evaluate oncologic theranostics made from its HetSiFA platform.
  • Fuzionaire Dx creates theranostic candidates by combining its HetSiFAs, or heteroaromatic silicon-fluoride acceptors, with cancer-targeting peptides and other ligands.
  • McMaster University is among Canadas most research-intensive universities and is consistently ranked as one of the worlds Top 100 universities.

8 out of 10 Canadians are concerned about the impact of misinformation on parents’ decisions about their child’s health

Retrieved on: 
Thursday, June 9, 2022
Vaccination, Pediatrics, Parent, Adult, McMaster, Research, Child, Ageing, CEO, Partnership, Public opinion, Government, Abacus Data, Investment, Vaccine, GLOBE, Hospital, Health, COVID-19, Chairperson, Social media, Population, House, Education, Toy, Medicine, Pharmaceutical industry

Parents want to make the best health decisions for their kids, and theyre calling on all levels of government for more accessible, timely and evidence-based child health information they can trust.

Key Points: 
  • Parents want to make the best health decisions for their kids, and theyre calling on all levels of government for more accessible, timely and evidence-based child health information they can trust.
  • Parents have been left scrambling to identify credible, science-based sources of information on everything from public health safety measures to vaccination, and Canadas kids are paying the price.
  • According to the survey, parents say childrens hospitals are their most trusted source for credible child and youth health information.
  • Collectively they provide national leadership in research and education to promote the health and healthcare of children and youth in Canada.

Audi teams up with three-Michelin-star Restaurant Noma and global nonprofit MAD to spark conversations around sustainability

Retrieved on: 
Tuesday, June 7, 2022
Mad Monday, Hammer Museum, Rexhepi, McMaster, Goal, Time, Program, MAD, Food, The World's 50 Best Restaurants, Knowledge, Michelin, Season, CEO, Partnership, NoMa, Meal, Environment, RO, Climate, Organization, City, Solution, Creativity, Multimedia, Future, Appetite, Student, Hammer Museum (Haines, Alaska), Academy, Pleasure, Publication, Health, Book, Restaurant, The New York Times, Foundation, Industry, Learning, VILD, New Nordic Cuisine, Fermentation, CO2, Philosophy, View, Biodiversity, World, Nightclub, Hotel, Management, Creative industries, Tourism, Symposium, Noma, Audi

Three-Michelin-star Restaurant Noma and its founder, Danish chef Ren Redzepi, are known for a focus on foraging, innovation and a unique interpretation of New Nordic Cuisine.

Key Points: 
  • Three-Michelin-star Restaurant Noma and its founder, Danish chef Ren Redzepi, are known for a focus on foraging, innovation and a unique interpretation of New Nordic Cuisine.
  • Collaborating with noma strengthens Audi's mission to work with like-minded organizations that stand for living progress and creating a more sustainable future.
  • Audi and noma share a commitment to sustainability and inclusion through actions grounded in purpose and a focus on creating a positive impact for individual and society as a whole.
  • MAD was founded in Copenhagen, Denmark, in 2011 by Ren Redzepi, chef and owner of restaurant noma, with the ambition of transforming hospitality and driving change in food systems.

Century Therapeutics to Host Virtual Research and Development Day on June 13, 2022

Retrieved on: 
Monday, June 6, 2022
Adult, McMaster, Glossary, B cell, R, Ink, Security (finance), U.S. Securities and Exchange Commission, GBM, Private Securities Litigation Reform Act, IPSC, Hamilton Health Sciences, Therapy, GLOBE, Century, Genetic engineering, NASDAQ, Research and development, Hospital, Event, Cancer, Pharmaceutical industry, Biochemistry

PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will host a virtual Research and Development (R&D) Day on Monday, June 13, 2022, from 4:30 PM to 6:00 PM ET.

Key Points: 
  • PHILADELPHIA, June 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will host a virtual Research and Development (R&D) Day on Monday, June 13, 2022, from 4:30 PM to 6:00 PM ET.
  • The event will focus on the Companys next-generation iPSC-based cell therapy platform technologies and includes a discussion on its strategy in GBM with CNTY-103.
  • For additional information on how to access the event, please visit the Events & Presentations section of Centurys website.
  • Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers.

BeMo Launches $100K Ace the MCAT & Get into Med School Competitions

Retrieved on: 
Wednesday, June 1, 2022
Bemo, MCAT, Dream, Blog, McMaster, Time, AAMC, Program, School, Research, Altus, Doctor of Philosophy, Lists of schools in England, CEO, CASPer, UK–Australia FTA, Student, UK, Review, Gold, Education, University, Medicine, Life insurance, Platinum

The Ace the MCAT & Get into Med School competitions begin on June 1, 2022, and run until October 31, 2022.

Key Points: 
  • The Ace the MCAT & Get into Med School competitions begin on June 1, 2022, and run until October 31, 2022.
  • The two contests are running simultaneously, each with a prize of $50,000, or a $100,000 grand prize for the contestant that wins both competitions.
  • Here're the details:
    The Ace the MCAT competition $50,000 prize will be awarded to a student who gets the highest MCAT score from the total pool of contestants on the official AAMC MCAT taken between June 1st, 2022, and December 31st, 2022.
  • BeMo helps students with applications, MCAT, CASPer, interviews, shadowing experience, research experience, and much more.

BeMo Launches $100K Ace the MCAT & Get into Med School Competitions

Retrieved on: 
Wednesday, June 1, 2022
Bemo, MCAT, Dream, Blog, McMaster, Time, AAMC, Program, School, Research, Altus, Doctor of Philosophy, Lists of schools in England, CEO, CASPer, UK–Australia FTA, Student, UK, Review, Gold, Education, University, Medicine, Life insurance, Platinum

The Ace the MCAT & Get into Med School competitions begin on June 1, 2022, and run until October 31, 2022.

Key Points: 
  • The Ace the MCAT & Get into Med School competitions begin on June 1, 2022, and run until October 31, 2022.
  • The two contests are running simultaneously, each with a prize of $50,000, or a $100,000 grand prize for the contestant that wins both competitions.
  • Here're the details:
    The Ace the MCAT competition $50,000 prize will be awarded to a student who gets the highest MCAT score from the total pool of contestants on the official AAMC MCAT taken between June 1st, 2022, and December 31st, 2022.
  • BeMo helps students with applications, MCAT, CASPer, interviews, shadowing experience, research experience, and much more.

McMaster University, Ultra Safe Nuclear Corporation, and Global First Power Sign MOU to Study Deployment of Micro Modular Reactor (MMR®)

Retrieved on: 
Wednesday, May 18, 2022
Zero, Knowledge, University, MOU, Electricity, Health, SMR, Western world, Graphite-moderated reactor, Research, National Nuclear Laboratory, Industry, Partnership, McMaster, MMR, Student, McMaster University, Safety, Technology, Waste management, OPG, Adoption, Ontario Power Generation, Nuclear energy, Canadian Nuclear Safety Commission, CNL, GFP, CEO, Renewable energy, Chalk River

The three partners have signed a Memorandum of Understanding (MOU) to further examine the feasibility of deploying a Micro Modular Reactor (MMR) at McMaster University or an affiliated site.

Key Points: 
  • The three partners have signed a Memorandum of Understanding (MOU) to further examine the feasibility of deploying a Micro Modular Reactor (MMR) at McMaster University or an affiliated site.
  • The MMR is a new class of nuclear reactor, much smaller in size and power than traditional nuclear reactors, with enhanced safety features.
  • Ultra Safe Nuclear Corporation (USNC) is the Seattle-based global leader in the deployment of micro reactors, with its Canadian operations headquartered in Ottawa, Ontario.
  • USNC's proprietary Micro Modular Reactor (MMR) Energy System can provide electricity or process heat to heavy industry and remote communities.

Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Monday, May 16, 2022
Food, Research, IPSC, U.S. Securities and Exchange Commission, Bristol Myers Squibb, Hamilton Health Sciences, Exposition, Conference, IPR, Risk, American Society of Gene and Cell Therapy, GAAP, Private Securities Litigation Reform Act, CAR, Cancer, Research and development, BMS, CD22, Annual general meeting, G&A, Genetic engineering, Investment, Therapy, CGMP, COVID-19, Marketing, Century, Food and Drug Administration, NK, Collaboration, GLOBE, GBM, Ink, Company, Hospital, Adult, McMaster, CRISPR, Maintenance, Administration, Cell, CD19, Security (finance), Aggressive lymphoma, B cell, R, Patient, NASDAQ, Society, Glossary, Gene, IND, Intellectual property, Glioblastoma, Indolent lymphoma, Pharmaceutical industry, Cryptocurrency, Biochemistry

PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc., (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the first quarter ended March 31, 2022.

Key Points: 
  • - Ended first quarter 2022 with cash, cash equivalents, and investments of $466.4M; Cash runway into 2025 -
    PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics , Inc., (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the first quarter ended March 31, 2022.
  • We are off to a strong start in 2022, which we expect will be a transformational year for Century as we transition into a clinical-stage organization, said Lalo Flores, Chief Executive Officer, Century Therapeutics.
  • The Companys current Good Manufacturing Practice (cGMP) manufacturing facility in Branchburg, New Jersey is expected to be operational in 2022.
  • We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations.

Gulf Breeze Zoo Welcomes Baby Orangutan, Satu

Retrieved on: 
Tuesday, May 3, 2022
McMaster, List of highways numbered 98, Zoo, Male, Congress, Animal, Multimedia, Female, Gulf Breeze Zoo, Gulf Breeze Zoo

GULF BREEZE, Fla., May 3, 2022 /PRNewswire/ -- The Gulf Breeze Zoo is excited to announce the recent birth of a male orangutan named Satu born January 20 to mom, Sara, and dad, Louie.

Key Points: 
  • GULF BREEZE, Fla., May 3, 2022 /PRNewswire/ -- The Gulf Breeze Zoo is excited to announce the recent birth of a male orangutan named Satu born January 20 to mom, Sara, and dad, Louie.
  • "She is very curious about everything and everyone, especially the newest member of the orangutan congress, Satu," said Jamie McMaster, Gulf Breeze Zoo Director.
  • The Gulf Coast Area's award-winning Gulf Breeze Zoo is home to more than 1200 exotic animals, many of them threatened and endangered.
  • The Gulf Breeze Zoo opens at 9 a.m. daily and is located just off Highway 98, Gulf Breeze FL.

MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products

Retrieved on: 
Tuesday, April 5, 2022
Company, Family, Methicillin-resistant Staphylococcus aureus, FSE, Cannabinoid, Investment, Marketing, OTCQX, White, Forward-looking statement, Legislation, Multimedia, Adult, SEDAR, Bacteria, Mouse, THC, Failure, API, TSX, View, Citrus, Natural health product, Industry, CBG, CBN, CBD, Appalachia, Traction, Taste, Phrase, ISO, Medication, News, Infection, Development, Water, Good, MRSA, Research and development, Patient, McMaster, Online shopping, Pharmaceutical industry, Fine chemical, Research, Northbound

MediPharm continues to lead the industry in CBN products.

Key Points: 
  • MediPharm continues to lead the industry in CBN products.
  • BARRIE, ON, April 5, 2022 /PRNewswire/ -MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs", "MediPharm" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the expansion of its adult use wellness product line with the launch of CBG and water-soluble products.
  • As of today, these new products will be available in Ontario in both retail stores and on the OCS.ca e-commerce website.
  • MediPharm also has purchase commitments to distribute the products to the Company's other seven provincial distributors in the coming months.